1. Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors.
- Author
-
Ran He, Sandford, Gordon, Hayward, Gary S., Burns, William H., Posner, Gary H., Forman, Michael, and Arav-Boger, Ravit
- Subjects
- *
CYTOMEGALOVIRUS diseases , *LUCIFERASES , *DNA polymerases , *VIRUS diseases , *DEOXYRIBOSE - Abstract
Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28- luciferase virus achieved a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque reduction and real-time PCR. The pp28-luciferase reporter system is rapid, reproducible, and highly sensitive. It may be applied to screening of novel anti-CMV compounds. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF